EMA Authorised: Zoledronic acid Actavis (zoledronic acid monohydrate) — Actavis Group PTC ehf

View source ↗

Summary

The EMA authorised Zoledronic acid Actavis (zoledronic acid monohydrate) for therapeutic use in fractures and bone-related conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Disorders
• Fractures

Drugs mentioned

• Zoledronic acid Actavis (zoledronic acid monohydrate)

Snippet

Status: Authorised. Therapeutic area: Fractures, Bone. MAH: Actavis Group PTC ehf. Decision date: 31/05/2023